Related Experiment Video
Updated: Jul 7, 2026
08:17
A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
Published on: August 15, 2019
CD70 as a therapeutic target in human malignancies
1Seattle Genetics, Inc., Department of Preclinical Therapeutics, 21823 30th Drive SE, Bothell, Washington 98021, USA. igrewal@seagen.com
Expert Opinion on Therapeutic Targets
|February 14, 2008
Summary
Targeting CD70 with antibody-based therapies, including antibody-drug conjugates, shows significant promise for treating various cancers. Preclinical models demonstrate potent antitumor activity, validating CD70 as a key therapeutic target in malignancies.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- CD70, a tumor necrosis factor superfamily member, is expressed on activated immune cells and various cancers.
- Its restricted normal tissue expression and widespread malignancy presence make CD70 an attractive therapeutic target.
- Research has identified anti-CD70 antibodies as potential clinical candidates for cancer treatment.
Purpose of the Study:
- To review CD70 expression in cancer cells.
- To describe the development of antibody-based therapies targeting CD70.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of antibody-based therapeutic strategies against CD70.
- Evaluation of animal models for anti-CD70 therapies.
Main Results:
- Humanized anti-CD70 antibodies demonstrated significant antitumor effects in preclinical cancer models.
- Anti-CD70 antibody-drug conjugates showed potent antitumor activity in solid tumor models.
- Cytotoxic drug delivery via antibodies enhances therapeutic efficacy.
Conclusions:
- Targeting CD70 with unconjugated antibodies or antibody-drug conjugates is a promising strategy for treating human malignancies.
- Preclinical data strongly support CD70 as a viable target for antibody-based cancer therapeutics.
- Further development of CD70-targeted therapies holds potential for improved cancer treatment outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...